Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 24, 2022 04:50 ET | Source: The Insight Partners

Peripheral Vascular Devices Market Size, $17,679.72 Million by 2028 Lead by Peripheral Vascular Stents, 6.5% CAGR - Exclusive Research Report by The Insight Partners

New York, Jan. 24, 2022 (GLOBE NEWSWIRE) -- According to our new research study on “Peripheral Vascular Devices Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product (Peripheral...
October 27, 2020 05:00 ET | Source: Global Market Insights, Inc

Interventional Cardiology & Peripheral Vascular Devices Market to hit $32.5 Bn by 2026: GMI

Selbyville, Delaware, Oct. 27, 2020 (GLOBE NEWSWIRE) -- According to latest report “Interventional Cardiology & Peripheral Vascular Devices Market by product (Interventional Catheters,...
March 02, 2020 14:00 ET | Source: Reports and Data

Cardiac Rehabilitation Market To Reach USD 2.29 Billion By 2026 | Reports and Data

New York, March 02, 2020 (GLOBE NEWSWIRE) -- According to the current analysis of Reports and Data, the cardiac rehabilitation market was valued at USD 1.37 billion in 2018 and is expected to reach...
November 10, 2016 08:00 ET | Source: Proteon Therapeutics, Inc.

Proteon Therapeutics Announces First Patient Dosed in Phase 1 Study Evaluating Vonapanitase for the Treatment of Peripheral Artery Disease Below the Knee

WALTHAM, Mass., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
October 25, 2016 08:00 ET | Source: Proteon Therapeutics, Inc.

Proteon Therapeutics Announces Overview of Phase 1 Clinical Program of Investigational Vonapanitase in Peripheral Artery Disease to be Presented at the 28th Transcatheter Cardiovascular Therapeutics (TCT) Conference

WALTHAM, Mass., Oct. 25, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
June 15, 2016 08:00 ET | Source: Proteon Therapeutics, Inc.

Proteon Therapeutics to Present at the JMP Securities Life Sciences Conference June 22nd

WALTHAM, Mass., June 15, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients...
April 13, 2016 08:00 ET | Source: Proteon Therapeutics, Inc.

Proteon Therapeutics Announces Publication in the Journal of Cardiovascular Pharmacology of Promising Nonclinical Results for Vonapanitase in Peripheral Artery Disease

WALTHAM, Mass., April 13, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
January 08, 2015 16:30 ET | Source: Proteon Therapeutics, Inc.

Journal of Cardiovascular Pharmacology Publishes Positive Nonclinical Results of Proteon Therapeutics' PRT-201 in Peripheral Artery Disease

WALTHAM, Mass., Jan. 8, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
November 04, 2012 20:52 ET | Source: American Heart Association

Non-Emergency Angioplasty Costs Higher in Hospitals Without Back-Up Surgery

Study highlights: Angioplasty costs for treating patients with stable symptoms are slightly higher in hospitals that do not have emergency heart surgery back-up, compared to those that do,...
May 11, 2012 09:00 ET | Source: American Heart Association

Multiple Factors Influence Five-Year Survival After Angioplasty, Bypass Procedures

FRIDAY NEWS TIP Embargoed for 9 a.m. ET ATLANTA, May 11, 2012 (GLOBE NEWSWIRE) --The effectiveness of heart bypass grafts and angioplasty procedures on five-year survival varies significantly...